<DOC>
	<DOCNO>NCT00862784</DOCNO>
	<brief_summary>The purpose study test long participant colorectal cancer live without progressive disease treat IMC-1121B ( ramucirumab ) modify FOLFOX-6 chemotherapy .</brief_summary>
	<brief_title>A Study IMC-1121B ( Ramucirumab ) Colorectal Cancer</brief_title>
	<detailed_description>The purpose study evaluate progression-free survival ( PFS ) participant metastatic colorectal cancer treat monoclonal antibody IMC-1121B ( ramucirumab ) combination modify FOLFOX-6 [ folinic acid ( FA ) + fluorouracil ( 5-FU ) + oxaliplatin , mFOLFOX-6 ] chemotherapy regimen first-line therapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>The participant must histologically confirm adenocarcinoma colon rectum locallyadvanced metastatic unresectable The participant least one unidimensionallymeasurable target lesion [ ≥ 2 centimeter ( cm ) conventional technique ≥ 1 cm spiral compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) , define Response Evaluation Criteria Solid Tumors ( RECIST ) ] ; target lesion ( ) must lie within irradiated area . Participants locally advance rectal carcinoma undergone previous radiation must document evidence disease progression pelvis order participate The participant age ≥ 18 year The participant life expectancy ≥ 6 month The participant Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 01 study entry The participant adequate hematologic function , evidence absolute neutrophil count ( ANC ) ≥ 1500/microliter ( μL ) , hemoglobin ≥ 10 grams/deciliter ( g/dL ) , platelets ≥ 100,000/μL The participant adequate hepatic function define : total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN ( 5.0 x ULN case liver metastasis ) , serum albumin ≥ low limit normal ( LLN ) institutional range ( &lt; LLN ) within 10 % LLN The participant adequate renal function define serum creatinine ≤ 1.5 x ULN , creatinine clearance ( measure via 24hour urine collection ) ≥ 60 milliliters/minute ( mL/min ) The participant 's urinary protein ≤ 1+ dipstick routine urinalysis [ ( UA ) ; urine dipstick routine analysis ≥ 2+ , 24hour urine protein must demonstrate &lt; 1000 milligram ( mg ) protein 24 hour allow participation study ] The participant must adequate coagulation function define International Normalized Ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 5 second ULN . Participants fulldose anticoagulation must stable dose oral anticoagulant low molecular weight ( LMW ) heparin warfarin , must INR 2 3 active bleed pathological condition present carry high risk bleeding ( example , tumor involve major vessel know varix ) The participant resolution Grade ≤ 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 3 ( NCICTCAE v 3.0 ) clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy exception peripheral neuropathy must resolve Grade 0 The participant agree use adequate contraception study period 8 week last dose study treatment The participant provide sign informed consent The participant receive prior systemic chemotherapy locallyadvanced unresectable metastatic colorectal cancer ( CRC ) . Prior adjuvant chemotherapy allow disease progression document &gt; 6 month end last cycle adjuvant chemotherapy &gt; 12 month end last cycle adjuvant oxaliplatincontaining regimens The participant document and/or symptomatic brain leptomeningeal metastases The participant participate clinical study nonapproved experimental agent procedure within 12 week study entry The participant receive previous therapy monoclonal antibodies The participant receive previous therapy agent target vascular endothelial growth factor ( VEGF ) VEGF receptor2 ( VEGFR2 ) ( include multitargeted tyrosine kinase inhibitor ) The participant ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , psychiatric illness/social situation , serious uncontrolled medical disorder opinion investigator The participant chronic nontopical corticosteroid treatment &gt; 6 month dose &gt; 10 mg/day prednisolone equivalent study entry , opinion investigator could compromise participant study The participant know dihydropyrimidine dehydrogenase ( DPD ) deficiency The participant know allergy treatment component The participant acute subacute intestinal obstruction The participant uncontrolled poorly control hypertension standard regimen antihypertensive therapy The participant concurrent active malignancy adequately treat nonmelanomatous skin cancer , noninvasive carcinoma , situ neoplasm . A participant previous history malignancy eligible , provide he/she disease free &gt; 3 year The participant , female , pregnant Has prior autologous allogeneic organ tissue transplantation Has interstitial pneumonia interstitial fibrosis lung , opinion investigator could compromise participant study Has pleural effusion ascites cause &gt; Grade 1 dyspnea Has psychological , familial , sociological , geographical condition permit adequate study followup , compliance protocol , signature Informed Consent Has undergone major surgery within 28 day prior first dose study medication , subcutaneous venous access device placement within 7 day prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Colorectal carcinoma</keyword>
	<keyword>CRC</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>